News & Updates
Filter by Specialty:
Aumolertinib a win in EGFR T790M-positive advanced NSCLC
The novel third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) aumolertinib appears to be effective in the treatment of patients with EGFR T790M-positive advanced nonsmall cell lung carcinoma (NSCLC) following progression on first- and second-generation EGFR TKI therapy, according to data from the phase II APOLLO Registrational Trial.
Aumolertinib a win in EGFR T790M-positive advanced NSCLC
23 Dec 2021
Time to prophylaxis linked to VTE incidence in traumatic brain injury patients
Most patients with traumatic brain injury receive delayed prophylaxis, with no association seen between incidence of venous thromboembolism (VTE) and prophylaxis regimen, suggests a study. However, a significant difference is observed in VTE incidence stratified by time to prophylaxis.
Time to prophylaxis linked to VTE incidence in traumatic brain injury patients
23 Dec 2021
Zolpidem, zopiclone help insomniac seniors with Alzheimer’s disease sleep
Short-term treatment with zolpidem or zopiclone in older patients with Alzheimer’s disease and insomnia appears beneficial, even though safety and tolerance issues have yet to be personalized in healthcare settings and further investigated in subsequent trials, according to a study.
Zolpidem, zopiclone help insomniac seniors with Alzheimer’s disease sleep
22 Dec 2021
TAF useful in pregnant women with chronic hepatitis B infection
Treatment with tenofovir alafenamide (TAF) for pregnant women with active chronic hepatitis B (CHB) infection, when administered throughout or initiated early in pregnancy, is effective and safe in both mothers and infants, according to a study.